CTMX (CytomX Therapeutics) Beginning Cash Position: $14.19 Mil (As of Mar. 2026)


CTMX CytomX Therapeutics Inc CTMX
36 GF Score
Price $3.85
GF Value $0.28
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is CytomX Therapeutics Beginning Cash Position?

CytomX Therapeutics CTMX +0.52% 36 Beginning Cash Position is $14.19 Mil as of Mar. 2026. GuruFocus rates CTMX with a GF Score™ of 36/100 and a GF Value™ of $0.28 (Significantly Overvalued). The stock has 4 warning signs investors should review.

CytomX Therapeutics's Beginning Cash Position for the quarter that ended in Mar. 2026 was $14.19 Mil.

CytomX Therapeutics's quarterly Beginning Cash Position declined from Sep. 2025 ($50.07 Mil) to Dec. 2025 ($35.21 Mil) and declined from Dec. 2025 ($35.21 Mil) to Mar. 2026 ($14.19 Mil).

CytomX Therapeutics's annual Beginning Cash Position declined from Dec. 2023 ($194.57 Mil) to Dec. 2024 ($18.09 Mil) but then increased from Dec. 2024 ($18.09 Mil) to Dec. 2025 ($39.08 Mil).

CytomX Therapeutics Beginning Cash Position Related Terms

CytomX Therapeutics Beginning Cash Position Historical Data

* Premium members only.

The historical data trend for CytomX Therapeutics's Beginning Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CytomX Therapeutics Beginning Cash Position Chart

CytomX Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beginning Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 192.78 206.45 194.57 18.09 39.08

CytomX Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beginning Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 39.08 48.63 50.07 35.21 14.19
CTMX
36GF Score
CytomX Therapeutics Inc CTMX
Beginning Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

CytomX Therapeutics Beginning Cash Position Calculation

Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement.

What does a Beginning Cash Position of $14.19 Mil mean?
CytomX Therapeutics (CTMX) has a Beginning Cash Position of $14.19 Mil as of Mar. 2026. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on CytomX Therapeutics and its competitors.
Is CytomX Therapeutics' Beginning Cash Position too high?
CytomX Therapeutics' current Beginning Cash Position is $14.19 Mil. Overall, CytomX Therapeutics has a GF Score™ of 36/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does CytomX Therapeutics' Beginning Cash Position compare to ALLO and XOMA?
CytomX Therapeutics' Beginning Cash Position of $14.19 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beginning Cash Position for a Biotechnology company?
A good Beginning Cash Position depends on the Biotechnology industry context. However, Beginning Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beginning Cash Position mean?
A high Beginning Cash Position can signal that a stock is expensive relative to its fundamentals. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on CytomX Therapeutics and its competitors. CytomX Therapeutics's current Beginning Cash Position is $14.19 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CytomX Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, CytomX Therapeutics (CTMX) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.28, compared to a current price of $3.85 — trading 1273.2% above its estimated fair value. The current Beginning Cash Position is $14.19 Mil. CytomX Therapeutics' overall GF Score™ is 36/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beginning Cash Position calculated?
Beginning Cash Position is calculated from a company's financial statements. For CytomX Therapeutics (CTMX), the current Beginning Cash Position is $14.19 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is CytomX Therapeutics (CTMX) Overvalued in 2026?

Based on GuruFocus' analysis, CytomX Therapeutics stock appears to be overvalued. The current stock price of $3.85 is trading 1273.2% above its estimated GF Value™ of $0.28. GuruFocus considers CytomX Therapeutics to be Significantly Overvalued.

Key valuation signals for CTMX:

  • Beginning Cash Position: $14.19 Mil
  • GF Value™: $0.28 vs. price of $3.85 (1273.2% above fair value)
  • GF Score™: 36/100 with 4 warning signs

No single metric tells the full story. See the CTMX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

CytomX Therapeutics Business Description

Other Exchanges 6C1:Germany
Address 151 Oyster Point Boulevard, Suite 400, South San Francisco, CA, USA, 94080
CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.
36GF Score

Get the complete analysis for CTMX

Beginning Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.85
Price
$0.28
GF Value